Trial Profile
Lutropin Alfa (Luveris) in Women at Risk of Poor Response Suppressed With Cetrorelix: an Exploratory Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Lutropin alfa (Primary) ; Cetrorelix; Follitropin alfa
- Indications Female infertility
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 05 May 2010 New trial record